Lannett Earnings, Revenue Miss in Q1
- ByInvesting.com-
Investing.com - Lannett (NYSE:LCI) reported on Wednesday first quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Lannett announced...
Investing.com - Lannett (NYSE:LCI) reported on Wednesday first quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Lannett announced...
Lannett (NYSE:LCI) reported Q2 EPS of ($0.44), $0.02 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $74.2 million versus the consensus estimate of...
Lannett Company (NYSEMKT:LCI) discloses that it will record an impairment charge in Q1 2019 of $27M - 33M in connection with its planned sale of its Cody API business.It says the...
Lannett (NYSE:LCI) LCI shares rallied 10.1% in the last trading session to close at $5.33. This move can be attributable to notable volume with a higher number of shares being...
Recent positive news about a COVID-19 vaccine has put the limelight on health-care and pharmaceutical companies, especially BioNTtech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA) and...
Radius Health, Inc. (NASDAQ:RDUS) reported encouraging results for the third quarter of 2019, wherein loss was narrower than expected and sales surpassed estimates.Shares of...
Lannett Company, Inc. is engaged in the development, manufacturing, marketing and distribution of generic versions of brand pharmaceutical products. The Company markets approximately 100 products, mainly tablet, capsule or liquid oral generic medications. Its marketed products include generics such as Posaconazole, Fluphenazine, Levothyroxine, Sumatriptan and NDA-based product Numbrino. The Company’s product portfolio include Amphetamine IR Tablets, which are used to treat Attention deficit hyperactivity disorder (ADHD) and narcolepsy; Dicyclomine tablets, used for the treatment of functional bowel disorder and irritable bowel syndrome; Levothyroxine Capsules, used to treat patients with hypothyroidism and other conditions, and Numbrino Nasal Solution, used for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults, among others.
| Average | 1.000 (+85.185% Upside) |
| High | 1.000 |
| Low | 1.000 |
| Price | 0.540 |
| No. of Analysts | 1 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 145.93 | 147.23 | 143.08 | +1.97 | +1.37% | 70.26M | NASDAQ | |||
| 248.15 | 249.83 | 246.83 | +0.15 | +0.06% | 25.98M | NASDAQ | |||
| 99.37 | 100.32 | 97.31 | +1.85 | +1.90% | 33.74M | NASDAQ | |||
| 28.16 | 28.24 | 26.78 | -1.93 | -6.41% | 147.99M | NASDAQ | |||
| 177.88 | 180.68 | 161.17 | +17.61 | +10.99% | 304.01M | NASDAQ | |||
| 102.24 | 103.49 | 99.53 | +3.02 | +3.04% | 86.77M | NASDAQ | |||
| 203.65 | 206.28 | 194.05 | +5.63 | +2.84% | 54.08M | NASDAQ | |||
| 8.89 | 8.97 | 8.89 | +0.110 | +1.25% | 2.91M | NYSE | |||
| 75.40 | 76.74 | 73.49 | +0.24 | +0.32% | 57.89M | NASDAQ | |||
| 140.57 | 141.36 | 139.29 | -0.58 | -0.41% | 6.87M | NYSE | |||
| 43.79 | 44.34 | 43.78 | -0.46 | -1.04% | 22.75M | NYSE | |||
| 70.20 | 70.64 | 69.77 | +0.03 | +0.04% | 544.18K | NASDAQ | |||
| 60.49 | 60.96 | 60.37 | -0.32 | -0.53% | 14.03M | NYSE | |||
| 115.94 | 117.12 | 108.73 | +6.52 | +5.96% | 9.55M | NASDAQ | |||
| 231.44 | 232.84 | 227.25 | +6.73 | +3.00% | 10.97M | NYSE |